Respira Therapeutics has granted Gossamer Bio an option to acquire the company, focusing on developing RT234, an investigational as-needed treatment for pulmonary hypertension. The agreement includes stock issuance and potential milestone payments.

Gossamer Bio has entered an option agreement to acquire Respira Therapeutics and its lead candidate RT234, an inhaled vardenafil therapy for pulmonary hypertension, with potential to expand its pulmonary hypertension treatment portfolio.

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.

The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.

XOMA Royalty Corporation has acquired Pulmokine Inc. for $20 million, adding the royalty and milestone interest in seralutinib, a Phase 3 asset being studied for pulmonary arterial hypertension, to its portfolio.

Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9. Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with its clean long-term safety profile, Oppenheimer said. Competitors like Merck & Co Inc’s (NYSE:MRK) Winrevair require frequent monitoring for hemoglobin increases, thrombocytopenia, and gastrointestinal bleeding. It may require dose reductions or drug holidays. In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib. Following the readout of the Phase 2 TORREY Study in patients with PAH, ...Full story available on Benzinga.com

This article highlights upcoming events in the financial world, including quarterly earnings reports, IPOs, investor events, and market volatility updates.

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Goldman Sachs has decided to maintain its Buy rating of Gossamer Bio (NASDAQ:GOSS) and lower its price target from $9.00 to $8.00. Shares of Gossamer Bio are trading up 0.69% over the last 24 hours, at $1.46 per share. A move to $8.00 would account for a 447.95% increase from the current share price. About Gossamer Bio Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary ...Full story available on Benzinga.com

HC Wainwright & Co. has decided to maintain its Buy rating of Gossamer Bio (NASDAQ:GOSS) and raise its price target from $5.00 to $10.00. Shares of Gossamer Bio are trading up 7.06% over the last 24 hours, at $0.91 per share. A move to $10.00 would account for a 998.9% increase from the current share price. About Gossamer Bio Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie ...Full story available on Benzinga.com

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer. Lantheus Holdings shares dipped 22.5% to $58.93 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Invivyd, Inc. (NASDAQ: IVVD) shares surged 170% to $4.40 after the company reported positive initial results from ongoing CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the Prevention of COVID-19. Cuentas Inc. (NASDAQ: CUEN) shares climbed 71.6% to $2.37. iCoreConnect Inc. (NASDAQ: ICCT) shares jumped 49.4% to $2.54 after surging over 73% on Friday. ZimVie Inc. (NASDAQ: ZIMV) gained 42.8% to $16.03 after the company disclosed an agreement to sell its spine business to H.I.G. Capital for $375 million. Biomerica, Inc. (NASDAQ: BMRA) climbed 42.4% to $1.41. Biomerica received FDA 510(k) clearance for its Hp Detect Stool Antigen ELISA test, designed to detect the presence of the H. pylori bacteria. Akso Health Group (NASDAQ: AHG) gained 41.6% to $0.8499. Energy Services of America Corporation (NASDAQ: ESOA) surged 35.4% to $4.7399 following FY23 earnings results. LQR House Inc. (NASDAQ: LQR) gained 30.9% to $3.3649. United States Steel Corporation (NYSE: X) rose 26.5% to $49.77 after Nippon Steel announced it will acquire the company for $55 per share in an all-cash transaction. Color Star Technology Co., Ltd. (NASDAQ: ADD) climbed 26.5% to $0.50. ZK International Group Co., Ltd. (NASDAQ: ZKIN) rose 22.3% to $1.26. Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR) shares gained 22.2% to $0.2750 after dipping around 24% on Friday. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) gained 21.3% to $2.96 after the FDA approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older. Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) climbed 20.5% to $0.6143. Noble Capital Markets ...

Penny stocks to buy according to these insiders in November 2023. The post 5 Penny Stocks To Buy Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.